BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7657527)

  • 1. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy.
    Eccles SA; Modjtahedi H; Box G; Court W; Sandle J; Dean CJ
    Invasion Metastasis; 1994-1995; 14(1-6):337-48. PubMed ID: 7657527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
    Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study.
    Shintani S; Funayama T; Yoshihama Y; Alcalde RE; Ootsuki K; Terakado N; Matsumura T
    Anticancer Res; 1995; 15(6B):2623-6. PubMed ID: 8669836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L; Xiang B; Muthuswamy SK
    Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.
    Kiguchi K; Bol D; Carbajal S; Beltrán L; Moats S; Chan K; Jorcano J; DiGiovanni J
    Oncogene; 2000 Aug; 19(37):4243-54. PubMed ID: 10980598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms.
    Kirschbaum MH; Yarden Y
    J Cell Biochem Suppl; 2000; 34():52-60. PubMed ID: 10762015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential.
    Mao W; Irby R; Coppola D; Fu L; Wloch M; Turner J; Yu H; Garcia R; Jove R; Yeatman TJ
    Oncogene; 1997 Dec; 15(25):3083-90. PubMed ID: 9444956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
    Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
    Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C; Lin H; Leonard SS; Shi X; Ye J; Luo J
    Oncogene; 2003 Aug; 22(34):5281-90. PubMed ID: 12917629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of HER receptors family in development and differentiation.
    Casalini P; Iorio MV; Galmozzi E; Ménard S
    J Cell Physiol; 2004 Sep; 200(3):343-50. PubMed ID: 15254961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
    Merrick DT; Kittelson J; Winterhalder R; Kotantoulas G; Ingeberg S; Keith RL; Kennedy TC; Miller YE; Franklin WA; Hirsch FR
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2281-8. PubMed ID: 16609045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells.
    Pu J; McCaig CD; Cao L; Zhao Z; Segall JE; Zhao M
    J Cell Sci; 2007 Oct; 120(Pt 19):3395-403. PubMed ID: 17881501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG; Hosick HL; Ethier SP
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.